Evidence for the contribution of non-covalent steroid interactions between DNA and topoisomerase in the genotoxicity of steroids

References

• Bolton JL, Trush MA, Penning TM, et al. (2000). Role of quinines in toxicology. Chem Res Toxicol 13:135–160
   PubMed Web of Science ®Google Scholar
• Chandrasekhar B, Mrigank AM, Kothekar V. (1987). On the possible mechanism of recognition of DNA base sequence by steroid hormones. FEBS 225:151–158
   PubMed Web of Science ®Google Scholar
• Classen S, Olland S, Berger JM. (2003). Structure of the topoisomerase II ATPase region and its mechanism of inhibition by the chemotherapeutic agent ICRF-187. Proc Natl Acad Sci USA 100:10629–10634
   PubMed Web of Science ®Google Scholar
• Cohen P, Chin R-C, Kidson C. (1969). Interactions of hormonal steroids with nucleic acids. II. Structural and thermodynamic aspects of DNA binding. Biochemistry 8:3603–3610
   PubMed Web of Science ®Google Scholar
• Cornelius F, Mahmoud YA. (2008). Interaction between cardiotonic steroids and Na,K-ATPase. Effects of pH and Ouabain-induced changes in enzyme conformation. Biochemistry 49:10056–10065
   Google Scholar
• Dorn SB, Degen GH, Muller T, et al. (2007). Proposed criteria for specific and non-specific chromosomal genotoxicity based on hydrophobic interactions. Mutat Res 628:67–75
   PubMed Web of Science ®Google Scholar
• Fortune JM, Osheroff N. (1998). Merbarone inhibits the catalytic activity of human topoisomerase II alpha by blocking DNA cleavage. J Biol Chem 273:17643–17650
   PubMed Web of Science ®Google Scholar
• Gomez L, Hack MD, Wu J, et al. (2007). Novel pyrazole derivatives as potent inhibitors of type II topoisomerases. Part 1: Synthesis and preliminary SAR analysis. Biorg Med Chem Lett 17:2723–2727
   PubMed Web of Science ®Google Scholar
• Hasinoff BB, Creighton AM, Kozlowska H, et al. (1997). Mitindomide is a catalytic inhibitor of DNA topoisomerase II that acts at the bisdioxopiperazine binding site. Mol Pharmacol 52:839–845
   PubMed Web of Science ®Google Scholar
• Hendry LB, Bransome ED Jr, Lehner AF, et al. (1986). The stereochemical complementarity of DNA and reproductive steroid hormones correlates with biological activity. J Steroid Biochem 26:843–852
   Google Scholar
• Hendry LB, Chu CK, Rosser JA, et al. (1994). Design of novel antiestrogens. J Steroid Biochem Mol Biol 49:269–280
   PubMed Web of Science ®Google Scholar
• Hendry LB, Mahesh VB. (1995). A putative step in steroid hormone action involves insertion of steroid ligands into DNA facilitated by receptor proteins. J Steroid Biochem Mol Biol 55:173–183
   PubMed Web of Science ®Google Scholar
• Hendry LB, Mahesh VB, Bransome ED Jr, Ewing DE. (2007). Small molecule intercalation with double stranded DNA: implications for normal gene regulation and for predicting the biological efficacy and genotoxicity of drugs and other chemicals. Mutat Res 623:53–71
   PubMed Web of Science ®Google Scholar
• Hendry LB, Witham FH, Chapman OL. (1977). Gene regulation: the involvement of stereochemical recognition in DNA-small molecule interactions. Perspec Biol Med 21:120–130
   PubMed Web of Science ®Google Scholar
• Hendry LB. (1988). Stereochemical complementarity of DNA and steroid agonists and antagonists. J Steroid Biochem 31:493–523
   PubMedGoogle Scholar
• Herman MB, Rajkhowa T, Cutuli E, et al. (2010). Regulation of renal proximal tubule Na-K-ATPase by prostaglandins. Am J Physiol Renal Physiol 298:1222–1234
   Web of Science ®Google Scholar
• Holt PA, Chaires JB, Trent JO. (2008). Molecular docking of intercalators and groove-binders to nucleic acids using Autodock and Surflex. J Chem Info Model 48:1606–1615
   Web of Science ®Google Scholar
• Hu T, Sage H, Hsieh T-S. (2002). ATPase domain of eukaryotic DNA topoisomerase II. J Biol Chem 277:5944–5951
   PubMed Web of Science ®Google Scholar
• Jensen LH, Thougaard AV, Grauslund M, et al. (2005). Substituted purine analogs define a novel structural class of catalytic topoisomerase II inhibitors. Cancer Res 65:7470–7477
   PubMed Web of Science ®Google Scholar
• Jensen LH, Renodon-Corniere A, Langer SW, et al. (2002). Maleimide is a potent inhibitor of topoisomerase II in vitro and in vivo: a new model of catalytic inhibition. Mol Pharmacol 61:1235–1243
   PubMed Web of Science ®Google Scholar
• Joosten HFP, Van Acker FAA, van den Dobbelsteen DJ, et al. (2004). Genotoxicity of hormonal steroids. Toxicol Lett 151:113–134
   PubMed Web of Science ®Google Scholar
• Kasper P. (2001). Cyproterone acetate: a genotoxic carcinogen?. Pharm Toxicol 88:223–231
   PubMedGoogle Scholar
• Kulling SE, Rosenberg B, Jacobs E, Metzler M. (1999). The phytoestrogens coumestrol and genistein induce chromosomal aberrations in cultured human peripheral blood lymphocytes. Arch Toxicol 73:50–54
   PubMed Web of Science ®Google Scholar
• Liehr JG. (2000). Is estradiol a genotoxic mutagenic carcinogen?. Endocr Rev 21:40–54
   PubMed Web of Science ®Google Scholar
• Long BH, Rose WC, Vyas DM, et al. (2002). Discovery of antitumor indolocarbazoles: rebeccamycin, NSC 655649 and fluoroindolocarbazoles. Curr Med Chem: Anti Cancer Agents 2:255–266
   PubMedGoogle Scholar
• Pastor N, Dominguez IK, Mateos S, Cortes F. (2002). A comparative study of genotoxic effects of anti-topoisomerase II drugs ICRF-193 and bufalin in Chinese hamster ovary cells. Mutat Res 515:171–180
   PubMed Web of Science ®Google Scholar
• Ricci CG, Netz PA. (2009). Docking studies on DNA-ligand interactions: building and application of a protocol to identify the binding mode. J Chem Info Modeling 49:1925–1935
   PubMed Web of Science ®Google Scholar
• Russo J, Russo IH. (2004). Genotoxicity of steroidal estrogens. Trends Endocrinol Metab 15:211–214
   PubMed Web of Science ®Google Scholar
• Sidell N, Tanmahasamut P, Ewing DE, Hendry LB. (2005). Transcriptional inhibition of the estrogen response element by antriestrogenic piperidinediones correlates with intercalation into DNA measured by energy calculations. J Steroid Biochem Mol Biol 96:335–345
   PubMed Web of Science ®Google Scholar
• Snyder RD, Ewing DE, Hendry LB. (2006). DNA intercalative potential of marketed drugs testing positive in in vitro cytogenetics assays. Mutat Res 609:47–59
   PubMed Web of Science ®Google Scholar
• Snyder RD, Arnone MR. (2002). Putative identification of functional interactions between DNA intercalating agents and topoisomerase II using the V79 in vitro micronucleus assay. Mutat Res 503:231–235
   Web of Science ®Google Scholar
• Snyder RD, Ewing DE, Hendry LB. (2004). Evaluation of DNA intercalative potential of pharmaceuticals and other chemicals by cell-based and three-dimensional computational approaches. Environ Mol Mutagen 44:163–173
   PubMed Web of Science ®Google Scholar
• Snyder RD, Holt PA, Maguire JM, Trent JO. (2013). Prediction of non-covalent Drug/DNA interaction using computational docking models: studies with over 1350 launched drugs. Environ Mol Mutagen 54:668–681
   PubMed Web of Science ®Google Scholar
• Snyder RD. (2000). Use of catalytic topoisomerase II inhibitors to probe mechanisms of chemical induced clastogenicity in Chinese hamster V79 cells. Environ Mol Mutagen 35:13–21
   PubMed Web of Science ®Google Scholar
• Snyder RD. (2007). Assessment of atypical DNA intercalating agents in biological and in silico systems. Mutat Res 623:72–82
   PubMed Web of Science ®Google Scholar
• Wiener JM, Gomez L, Venkatesan H, et al. (2007). Tetrahydroindazole inhibitors of bacterial type II topoisomerases. Part 2: SAR development and potency against multidrug-resistant strains. Bioorg Med Chem Lett 17:2718–2722
   PubMed Web of Science ®Google Scholar